Invesco
BBIO icon

Invesco’s BridgeBio Pharma BBIO Stock Holding History

Invesco’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$341M Sell
4,592,814
-238,491
-5% -$17.3M 0.03% 477
2025
Q4 		$370M Buy
4,831,305
+902,648
+23% +$59.3M 0.03% 411
2025
Q3 		$204M Buy
3,928,657
+1,127,592
+40% +$55M 0.03% 658
2025
Q2 		$121M Buy
2,801,065
+594,902
+27% +$21.6M 0.02% 775
2025
Q1 		$76.3M Buy
2,206,163
+1,313,036
+147% +$44.3M 0.01% 876
2024
Q4 		$24.5M Buy
893,127
+35,670
+4% +$922K ﹤0.01% 1385
2024
Q3 		$21.8M Sell
857,457
-231,263
-21% -$6.07M ﹤0.01% 1430
2024
Q2 		$27.6M Buy
1,088,720
+90,095
+9% +$2.46M 0.01% 1277
2024
Q1 		$30.9M Sell
998,625
-273,911
-22% -$9.32M 0.01% 1242
2023
Q4 		$51.4M Buy
1,272,536
+112,383
+10% +$3.38M 0.01% 992
2023
Q3 		$30.6M Buy
1,160,153
+475,684
+69% +$13.5M 0.01% 1157
2023
Q2 		$11.8M Buy
684,469
+631,161
+1,184% +$9.5M ﹤0.01% 1697
2023
Q1 		$884K Buy
53,308
+10,681
+25% +$125K ﹤0.01% 2952
2022
Q4 		$325K Sell
42,627
-276,255
-87% -$2.64M ﹤0.01% 3477
2022
Q3 		$3.17M Buy
318,882
+275,673
+638% +$2.86M ﹤0.01% 2440
2022
Q2 		$392K Sell
43,209
-981
-2% -$8.21K ﹤0.01% 3448
2022
Q1 		$449K Sell
44,190
-3,649
-8% -$37.4K ﹤0.01% 3447
2021
Q4 		$798K Sell
47,839
-5,027
-10% -$213K ﹤0.01% 3186
2021
Q3 		$2.48M Buy
52,866
+6,207
+13% +$333K ﹤0.01% 2715
2021
Q2 		$2.85M Buy
46,659
+22,185
+91% +$1.27M ﹤0.01% 2689
2021
Q1 		$1.51M Sell
24,474
-12,058
-33% -$789K ﹤0.01% 2890
2020
Q4 		$2.6M Buy
36,532
+30,631
+519% +$1.48M ﹤0.01% 2510
2020
Q3 		$222K Buy
+5,901
New +$186K ﹤0.01% 3427
2020
Q2 		– Sell
-9,792
Closed -$284K – 3643
2020
Q1 		$284K Buy
9,792
+2,941
+43% +$91.2K ﹤0.01% 3285
2019
Q4 		$240K Buy
+6,851
New +$190K ﹤0.01% 3493

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco's BBIO Position: Q1 2026 in Review

Invesco reduced its BridgeBio Pharma (BBIO) stake by 4.9% in Q1 2026, selling an estimated $17.3M and leaving 4,592,814 shares worth $341M. The position accounts for 0.03% of the portfolio, ranked #477.

Invesco first reported a position in BBIO in Q4 2019 and has held it in 25 quarters since. The position peaked at $370M in Q4 2025. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • Invesco held 4,592,814 shares of BridgeBio Pharma worth $341M as of Q1 2026.
  • Invesco sold 238,491 BridgeBio Pharma shares in Q1 2026, an estimated $17.3M.
  • BridgeBio Pharma made up 0.03% of Invesco's portfolio in Q1 2026, its #477 holding.
  • Invesco first reported a position in BridgeBio Pharma in Q4 2019 and has held it in 25 quarters since.
  • Invesco's BridgeBio Pharma position peaked at $370M in Q4 2025.
  • 457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.